Background Experiments were carried out using the new Na+-H+ exchange inhibitor (3-methylsulfonyl-4-piperidinobenzoyl)guanidine methanesulfonate (HOE 694) to assess the role of Na+-H+ exchange in myocardial ischemic and reperfusion injury.
Methods and Results Three groups of rabbit hearts (n=5 in each) were perfused with blood and were subjected to 45 minutes of global normothermic (37°C) ischemia, followed by 1 hour of reperfusion. Group 1 was the control group (vehicle only); in group 2, HOE 694 (1 ,umol/L) was administered before ischemia (pretreatment group); and in group 3, HOE 694 was given only during reperfusion to separate actions exerted during ischemia from those specifically obtained during reperfusion. End-diastolic pressure rise at 1 hour of reperfusion was reduced by administration of HOE 694 starting before ischemia (from 52 .2±8.5 mmHg in group 1 to 17.6±4.5 mm Hg in group 2, P<.01) or starting on reperfusion (28.8±5.4 mm Hg in group 3, P<.05 versus group 1). Left ventricular developed pressure (LVDP) and its derivative (dP/dt) recovered better in HOE 694-pretreated hearts (LVDP, 79±9.9 mm Hg in group 2 versus 24.8± 10 mm Hg in group 1; dP/dt, 1580±198 mm Hg/s versus 340±221 mm Hg/s, P<.01). In hearts treated only on reperfusion, some improvement was observed, which, however, did not reach statistical significance. Coronary flow on reperfusion was higher in groups 2 and 3 compared with controls, and no "no-reflow" was observed. Two additional groups of hearts were perfused with phosphate-free Krebs-Henseleit solution to enable studies with 31P nuclear magnetic resonance (NMR). ATP was better preserved in HOE 694-pretreated (62±4.9% of preischemic value) than in control hearts (44+3.3%) at the end of 30 minutes of reperfusion, and phosphocreatine resynthesis was higher (109±3.7% versus 86±5.4%). HOE 694 did not affect the time course of intracellular acidosis during ischemia but suppressed a small alkaline overshoot occurring early in reperfusion (pH 6 .96±0.02 in HOE 694-pretreated hearts versus 7.14±0.05 in control hearts). Electron microscopy with Ca21 staining of the blood-perfused hearts showed that clumping of Ca2' aggregates in mitochondria was prevented by HOE 694.
Conclusions Postischemic dysfunction was associated with a rise in end-diastolic pressure. This rise was effectively blocked by HOE 694. The drug was most effective when hearts were treated before ischemia, although partial protection was observed when administration was started on reperfusion. The action of HOE 694 strengthens the idea that Na+-H+ exchange during both ischemia and reperfusion contributes to contractile dysfunction. (Circulation. 1994; 89:2787 -2798 Key Words * sodium * ischemia * reperfusion .
imaging Complex processes take place in the intracellular and extracellular media during acute ischemia. High-energy phosphate stores are depleted and catabolites accumulate, resulting in intracellular and extracellular acidification. These changes may lead to a dysfunction of ionic pumps, transporters, and channels. During reperfusion, additional injury to the ischemia. Concentrations of lysophosphatidylcholine and palmitoylcarnitine increase rapidly during ischemia and may inhibit the pump. 5 The potential role of the Na+ channel as a pathway for excessive Na+ influx is still uncertain. Na+ channel blockade decreases the rise in intracellular Na+ (Reference 6) and delays the rise in resting tension during global ischemia.6,7 Some role for the Na+ current has been implicated from experiments performed on cardiac cells in conditions of "simulated" ischemia.8-1" The Na+-H+ exchanger has been proposed as an important source of Na4 entry during ischemia and reperfusion. Suppression of Na+-H+ exchange at the moment of reperfusion has been shown to protect the cells. Several investigators have reported that staged12"13 or acidotic14 reperfusion lessens myocardial stunning and reduces reperfusion-induced arrhythmias. 15 Mildly acidotic cardioplegic solutions result in better postarrest cardiac performance.'6 Also, suppression of intracellular proton production by glycogen deprivation has been shown to protect against ischemia and reperfusion injury. 17 The role of Na+-H+ exchange has also been determined by the application of Na+-H+ exchange blockers such as amiloride18 or its derivatives. Amiloride attenuates the rise in cytosolic Ca24 during ischemia'9 and prevents the sharp rise in Na+ and Ca24 content on reperfusion.20 Although the protective effects of amiloride against reperfusion arrhythmias and contractile dysfunction are well established, the contribution of the Na+-H+ exchanger to this effect is less clear because of the lack of specificity of amiloride. The drug has been reported to inhibit the Na+-K+ pump21 and the Na+-Ca24 exchanger.2223 It is known to block tetrodotoxin (TTX)-sensitive Na4 channels24 and the T-type Ca24 channel25 in the heart. The derivative ethylisopropylamiloride (EIPA) is more potent than amiloride but "side actions" still exist: its effect on Na4 channels is more marked.24 Definite proof of the contribution of Na+-H+ exchange to cell injury and contractile dysfunction is therefore complicated by the lack of specificity of the available Na+-H+ exchange blockers. HOE 694 [(3 -methylsulfonyl-4 -piperidinobenzoyl)guanidine methanesulfonate] is a new and potent Na+-H+ exchange blocker. This substance was characterized as an inhibitor of Na+-H+ exchange in rabbit erythrocytes, rat platelets, and bovine endothelial cells. 26 The drug recently was characterized as a competitive inhibitor of all three isoforms, NHE-1, NHE-2, and NHE-3, in fibroblast mutant cell lines in which different isoforms were expressed.27 The affinity was much higher for the ubiquitously expressed NHE-1 isoform, resulting in a better discrimination between different isoforms than the amiloride-related molecules. The compound has no effect on the Na4-Ca2+ exchange current in rat ventricular myocytes (H. Gogelein, personal communication). Although information on other currents in cardiac cells is missing, the absence of any inotropic effect under normoxic conditions28 makes it unlikely that intracellular Ca2+ is affected by this substance.
In the present study, we investigated the protective role of selective Na+-H+ exchange inhibition by HOE 694. Since reperfusion injury may be affected by processes occurring during ischemia or may relate to processes specifically present at the moment of reperfusion, we determined the efficacy of the novel Na+-H+ exchange blocker administered either before the onset of ischemia or only during reperfusion. Methods
Preparation
All animals received humane care in compliance with the "Principles of Laboratory Animal Care" formulated by the US National Society for Medical Research and the Guide for the Care and Use of Laboratory Animals prepared by the US National Academy of Sciences and published by the US National Institutes of Health (NIH publication No. 85-23, revised 1985) . New Zealand White rabbits (2.5 to 3 kg, male or female) were heparinized (1000 U IV), premedicated with fluanisone (2 mg/kg IM) and fentanyl (0.04 mg/kg IM), and anesthetized with sodium pentobarbital (25 mg/kg IV). After tracheotomy, the animals were ventilated with a mixture of room air and oxygen (Mark 7 ventilator, Bird). The thorax was opened through a midline sternotomy, and the heart and great vessels were excised and placed in ice-cold Ringer's solution. A cannula was inserted in the aorta, and the heart was mounted on the perfusion system. The time from excision to initiation of coronary perfusion was kept below 90 seconds. Initial studies were carried out in blood-perfused hearts to assess the effect of HOE 694 on postischemic functional recovery. For`P NMR spectroscopy, Krebs-Henseleit bufferperfused hearts were studied.
Blood-Perfused Hearts
Blood perfusion of isolated hearts has been described previously.29 Briefly, fresh heparinized rabbit blood was pumped from a venous reservoir through a plasma proteincoated membrane oxygenator (Oxim 11-06 infant hollow fiber membrane oxygenator, Jatene-Macchi) and through an arterial recirculation filter (37-,um pore diameter; Delta K-37, Healthdyne Cardiovascular). The coronary perfusion pressure was kept constant at 60 mm Hg via an overflow system and was monitored by a pressure transducer (model 1280, HewlettPackard). Coronary venous blood was collected in the venous reservoir and recirculated through the system. The blood was oxygenated with 95% 02-5% C02. Oxygen tension was kept between 300 and 550 mm Hg, and pH was between 7.30 and 7.45. A small cannula (Insyte-W 20G, Vialon) was inserted through the apex to decompress the left ventricle. Coronary flow was measured continuously with an in-line flow probe connected to a flowmeter (Transonic Systems, Inc). Myocardial temperature was monitored continuously with a probe (Ellab MKG-09500-A) inserted into the right ventricle near the interventricular septum. Left ventricular pressure (LVP) and its first derivative (LV dP/dt) were monitored through a fluid-filled balloon inserted in the left ventricle via the left atrium and connected to a pressure transducer (model 1280, Hewlett-Packard).
Krebs-Henseleit-Perfused Hearts in NMR
A modified Langendorif isolated heart system was used. The perfusate was pumped from a reservoir outside the NMR magnet through a blood transfusion filter (pore diameter, 40 ,um; Pall) to the perfusion column mounted close to the magnet. The heart was perfused via the cannulated aorta with a constant perfusion pressure of 60 mm Hg. Myocardial temperature was maintained at 37°C throughout the experiment.
The hearts were perfused with recirculating Krebs-Henseleit buffer ( 95% 02-5% C02, and the pH was 7.4. Po2 was kept above 550 mm Hg. The hearts were bathed in the effluent, which was evacuated from the top of the NMR cell by a peristaltic pump (Watson-Marlow). Coronary flow was measured by timed collection of the evacuated perfusate. Pressure measurements were made as in the blood-perfused hearts.
Experimental Protocol
After introduction of the balloon into the left ventricle, left ventricular end-diastolic pressure (LVEDP) was set at 7.2 mm Hg, and baseline hemodynamic measurements were made after a further stabilizing period of 15 minutes. Then the experiments in blood-perfused hearts were divided into three groups: one untreated group and two treated groups (n=5 in each group). In the untreated group (group 1), 4 mL of vehicle (Ringer's solution) was added in the venous reservoir. In the second group (group 2), 4 mL of a stock solution of 10-4 mol/L HOE 694 was added, yielding a final concentration of 10-6 mol/L HOE 694. Thereafter, hemodynamic changes were monitored continuously during 20 minutes before ischemia began. In the third group (group 3), the same dose of HOE 694 was administered to the isolated heart only on reperfusion. During the ischemic period, the blood was kept circulating through the overflow system. In group 3, the drug was infused in the venous reservoir 5 minutes before the start of reperfusion, allowing equal distribution of the drug at the onset of the reperfusion period. The amount of "dead space" was limited to the most distal part of the perfusion column (1.5 mL). Since coronary flow rose to 14 mL/min within 10 seconds of reperfusion in group 3, we may estimate that the delay time for entry of the drug into the heart was about 6 seconds. To rule out possible effects of rundown of the preparation, the same perfusion time was allowed in each group. Therefore, in group 3 the hearts were perfused for an additional 20 minutes after the first set of hemodynamic measurements before ischemia was started.
The HOE 694 dose used (10-6 mol/L) was found to be optimal for functional recovery in preliminary experiments on blood-perfused hearts, exposed to 10-7, 10-6, and 10-5 mol/L as final concentration in the perfusion system (n=3 in each group). A concentration of 10-7 mol/L conferred only minimal protection, whereas no additional protection beyond the one obtained with 10-6 mol/L was seen with 10`mol/L HOE 694.
To compare the effects of HOE 694 with those of the well-known Na+-H+ exchange inhibitor amiloride, an additional group was studied, in which 5.10-4 mol/L amiloride was administered throughout the experiment, following the same protocol as in group 2.
The aortic line was clamped to induce 45 minutes of global normothermic (37°C) ischemia. The intraventricular balloon was kept inflated throughout the ischemic period. During ischemic arrest, the hearts were submerged in another waterjacketed reservoir that was filled with Ringer's solution to keep the myocardial temperature at 37+0.50C.
Reperfusion was carried out for 60 minutes. Functional measurements were recorded continuously. At the end of the experiment, transmural biopsies were taken for high-performance liquid chromatographic (HPLC) measurements, and the hearts were disconnected from the perfusion system, flushed with 100 mL of saline via the aorta to wash out blood, and perfusion-fixed with 100 mL of 2.5% glutaraldehyde for morphological examination.
To assess the effect of HOE 694 on the metabolism of high-energy phosphates and intracellular pH, we studied two additional groups, using 31P NMR spectroscopy: one control group and one group treated with 10-6 mol/L HOE 694 before ischemia. The normothermic ischemic period in those groups was reduced to 30 minutes, since 45 minutes resulted in almost no functional recovery in this erythrocyte-free system. Reperfusion time was limited to 30 minutes, because a hemodynamic 31P NMR Spectroscopy Spectra were obtained in a 4.7-T, 30-cm-wide-bore horizontal magnet equipped with a Biospec spectrometer (Bruker, Spectrospin). Perfused hearts were placed in a cylindrical resonator (diameter, 30 mm), which was tuned to the 31P NMR frequency of 81.1 MHz.
Partially saturated 31P NMR spectra were acquired in blocks of 400 scans (5 minutes), using a 600 pulse (25 microseconds) with a 0.7-second repetition time. The total spectral bandwidth was 5 kHz. Before Fourier transformation, the accumulated free induction decays were multiplied with an exponential filter function corresponding to 15 ( 3-methylsulfonyl-4-piperidinobenzoyl)guanidine methanesulfonate (HOE 694) (group 2), amiloride (group 4), or 20 minutes after the baseline measurement, just before the start of ischemia (group 3). In the group in which HOE 694 was given on reperfusion only, control perfusion was continued for 20 minutes after the first set of hemodynamic measurements, and a second set of measurements was taken for comparison. Except for CF in the amiloride group, no significant differences were found among groups for other baseline hemodynamic parameters (*P<.001).
In the amiloride group, a steep increase of coronary flow (from 7.9±1.6 to 23.7±2.6 mL/min) was noted. Since this increase in coronary flow is not obtained with other Na'-HW exchange inhibitors, it can be explained by nonspecific effects of amiloride: a decrease in Na+ During ischemia, a progressive increase in LVEDP was noted in all groups (Fig 1) . The time of onset of ischemic contracture was defined as the time by which the end-diastolic pressure had increased by 2 The main feature in the recovery of postischemic function was a difference in end-diastolic pressure between control hearts on the one hand and treated hearts on the other. In the control group, LVEDP tended to decrease during the first 5 minutes of reperfusion, but afterward it increased again and remained elevated throughout the whole period of reperfusion. In the HOE 694-pretreated group, during reperfusion there was no further increase in diastolic tension, which gradually returned toward the preischemic value (end reperfusion, 18+4.4 mm Hg in HOE 694-treated hearts versus 51±8.6 mm Hg in control hearts). Also, in the hearts that were treated with HOE 694 only on reperfusion, no rise in end-diastolic pressure could be observed during reperfusion, although end-diastolic pressure levels remained slightly higher than in the pretreated group (end reperfusion, 29+5.4 mm Hg).
The LVEDP values obtained at the end of reperfusion are significantly lower than in the control group (Fig 1) .
Postischemic Recovery of Contraction
The pattern of recovery of left ventricular systolic pressure (LVSP) during reperfusion was different in control and treated hearts (Fig 2, top) (Table 2) . Differences in functional recovery are less marked than in blood-perfused hearts. Those hearts were perfused under less physiological circumstances, making them more vulnerable to ischemic and reperfusion damage and blunting the difference in functional recovery. However, the NMR studies were separate from the blood-perfused experiments. The conditions were based on the most useful ischemic timescale and the most effective HOE 694 perfusion period. Therefore, direct comparison between the NMR studies and the blood-perfused studies cannot be made.
Postischemic Coronary Flow Rate
In control hearts, the postischemic reactive hyperemia was moderate and reached a maximum value of 20.2±1.5 mL/min at 5 minutes of reperfusion. Afterward, the flow decreased and a condition of no-reflow was obtained after 20 minutes. At the end of reperfusion, the coronary flow was 6.5±1.8 mL/min, compared with 9.4±0.9 mL/min before ischemia (P<.001). The no-reflow was not observed in pretreated hearts (11.8±2.6 mL/min versus 8.8±1.5 mL/min before ischemia) or hearts treated during reperfusion only (8.7±2.1 mL/min versus 7.8±0.4 mL/min before ischemia).
In both treated groups, reactive hyperemia was more pronounced, and a higher coronary flow rate was recorded throughout the reperfusion phase. Significant differences were obtained at 10 minutes of reperfusion: 12 (Fig 4, top) . At In the untreated hearts, functional deterioration after 45 minutes of normothermic ischemia followed by 1 hour of reperfusion was accompanied by substantial evidence of irreversible damage (Fig 6A) : virtually all mitochondria were swollen, and cristae were in disarray or their structure had completely disappeared. Nearly all mitochondria showed amorphous matrix densities, consisting of precipitated calcium, indicative of irreversible injury. Sarcoplasmic swelling and myofibrillar swelling also were present.
Hearts pretreated with HOE 694 showed signs of reversible injury only. Mitochondrial swelling was present as well as localized disorganization of cristae. Mitochondria and myofibrils were more loosely packed than in the nonischemic condition. This coincides with some cell swelling. However, clumping of calcium precipitates in the matrix, a sign of irreversible damage, was totally absent (Fig 6B) .
In hearts treated with HOE 694 on reperfusion only, histological changes represented an intermediate condition between the untreated and the pretreated hearts. Some mitochondria contained clumps of calcium precipitate, indicating that injury became irreversible. However, those amorphous densities were not present in all the mitochondria within a given heart. Compared with pretreated hearts, the sarcolemma exhibited more extensive damage with some focal discontinuities (Fig 6C) . Discussion In the present study, we have investigated the beneficial effect of HOE 649 on ischemic and postischemic damage in isolated rabbit hearts. HOE 694 is a potent Na+-H+ exchange inhibitor with a high affinity for the NHE-1 isoform27: at physiological sodium concentrations, the KD for inhibition of the exchanger is in the micromolar range,36 while that of amiloride is in the millimolar range. 35 Although HOE 694 and EIPA have similar potencies for inhibiting Na'-HW exchange, HOE 694 has the advantage over EIPA of being more specific (see the introduction). HOE 694 was used as a tool to assess the role of Na+-H+ exchange in ischemia and reperfusion injury.
HOE 694 is effective in protecting the heart against stunning after short-term ischemia.37 Our data on functional recovery in blood-perfused rabbit hearts after an extended normothermic ischemia indicate that HOE 694 reduces ischemia and reperfusion injury of the myocardium. Pretreatment with HOE 694 significantly delayed the time of onset of ischemic contracture. Furthermore, the level of diastolic tension reached at 45 FIG 6 . Effect of ischemia and Na+-H+ exchange inhibition on ultrastructural changes of the myocardium. The bars denote 1 gm. Original magnification x 14 000. A, Photomicrograph of control myocardium after 45 minutes of ischemia followed by 1 hour of reperfusion. Myofibrils are severely stretched. The sarcoplasm is quite swollen, as shown by the pronounced separation of organelles. Glycogen is nearly absent. Virtually all mitochondria are swollen; cristae are in disarray or their structure has completely disappeared. Nearly all mitochondria show amorphous matrix densities, consisting of precipitated calcium, indicating irreversible ischemia and reperfusion injury. B, Photomicrograph of myocardium pretreated with (3-methylsulfonyl-4-piperidinobenzoyl)guanidine methanesulfonate (HOE 694 Inhibition of Na+-H+ exchange is most effective when already performed during the ischemia period, although protective effects of Na+-H+ exchange inhibition at reperfusion only have been reported. HOE 694, when used during reperfusion, decreases the incidence of reperfusion arrhythmias38,39 and reperfusion stunning39 in the isolated rat heart model. Acidotic reperfusion, which is known to block Na+-H+ exchange, protects the heart against reperfusion injury.14 This contrasts with recent findings of Karmazyn,18 who was unable to show protection by amiloride given at the moment of reperfusion. However, in these experiments a decrease in coronary perfusion pressure was noted in hearts treated with amiloride on reperfusion, which could account for impaired recovery of left ventricular function (Gregg's phenomenon). Also, Du Toit and Opie39 showed in the isolated working rat heart model that stunning could be lessened by administration of HOE 694 on reperfusion only, whereas amiloride had no effect on stunning when given in the reperfusion period only. This suggests that the absence of effect with amiloride is caused by a nonspecific, negative inotropic action of amiloride, which is absent in HOE 694. Although we know of no such data for cardiac myocytes, it has been reported33 that amiloride directly inhibits (by accumulation in the tissue) smooth muscle myosin light chain kinase reaction.
Acidotic reperfusion may attenuate myocardial stunning by mechanisms other than Na+-H+ exchange inhibition. An Karmazyn18 found a substantial reduction in CK release in hearts treated with amiloride. On the other hand, Murphy et al19 showed that amiloride did not alter CK release when hearts were reperfused after 60, 90, or 150 minutes of ischemia. However, in our electron microscopy images, focal discontinuities of the sarcolemma were more frequent in control than in HOE 694-treated hearts. This, together with the absence of calcium clumping in the mitochondria of pretreated hearts or substantial reduction of clumping in hearts treated during reperfusion, suggests that lethal damage is at least delayed by treatment with HOE 694.
The absence of a difference in ATP breakdown during ischemia between HOE 694-treated and control hearts is consistent with the reported absence of an effect of amiloride on ATP breakdown during ischemia or anoxia.19'23 On reperfusion, further breakdown of ATP levels was observed in control hearts, whereas a tendency for ATP resynthesis in HOE 694-pretreated hearts was noted. Since Na+ and Ca21 overload are less evident in treated hearts, less ATP will be consumed for extrusion of Na+ ions and Ca21 storage in the sarcoplasmic reticulum.
Also, the PCr content on reperfusion of HOE 694-treated hearts was higher than that of control hearts, indicating better preservation of mitochondrial function. PCr resynthesis from inorganic phosphate and creatine produces a proton that may help to suppress the alkaline overshoot in the HOE 694-treated hearts. The fact that the concentration of PCr is at least as high as in the control, preischemic condition indicates that the phosphorylation potential recovered. ATP, however, did not recover completely, indicating a loss in total adenylate pool.
Conclusions
Treatment with HOE 694 results in a marked improvement of contractile and metabolic functions during reperfusion. This beneficial effect is best explained by the decrease in Na+ influx during ischemia as well as during reperfusion, resulting in a decrease in calcium overload during reperfusion in HOE 694-treated hearts.
Because of the absence of obvious other effects, this drug may become an important tool in understanding cell damage during ischemia and reperfusion, underlining the role of primary Na+ and secondary Ca21 overload. Provided that toxicity to other organs is absent, HOE 694 has an interesting therapeutic profile in both the fields of cardiology and cardiac surgery: for the cardiologist, reducing Ca21 overload may be helpful in treating chronic ischemic heart disease; for the cardiac surgeon, it would be a welcome adjuvant drug when intermittent crossclamping of the aorta is used for coronary artery bypass surgery.67 Its addition to cardioplegic solutions may improve postarrest cardiac function. It counteracts the detrimental increase in Ca21 overload during transient episodes of ischemia and reperfusion.
